Anti-Infectives Market Size, Share, Growth and Forecast, 2025-2035

Anti-infectives market pivots to resistance and HIV care

The global anti-infectives market was valued at USD 157.47 billion in 2025 and is projected to increase from USD 163.96 billion in 2026 to USD 235.72 billion by 2035, registering a CAGR of 4.12% during 2026–2035. Demand rests on a large base of bacterial infections treated in hospitals and clinics, lifelong antiretroviral therapy for HIV, and recurring respiratory virus seasons that keep antiviral stocks moving. North America held the largest regional share, 36.0% in 2025, because branded HIV regimens and hospital antibiotics command higher prices there than elsewhere. Asia Pacific is the fastest-growing region at 5.10% a year, as insurance coverage widens and generic makers in India and China expand supply. The commercial picture changed in 2025, when U.S. regulators cleared the first twice-yearly HIV prevention injection and a first-in-class oral antibiotic for urinary infections. As a result, value is tilting toward long-acting antivirals and novel antibacterials that address resistant pathogens.

Which medicines and buyers does this analysis cover?

The analysis counts prescription antibiotics, antivirals, antifungals and antiparasitics used to treat or prevent infections in people, valued at manufacturer selling prices. Hospitals buy most parenteral agents through tenders and group purchasing contracts, while retail and online pharmacies dispense oral courses against prescriptions written in primary care. HIV medicines are counted for both treatment and pre-exposure prophylaxis, because the same originators and generic suppliers serve both uses.

Vaccines, disinfectants, antiseptics and veterinary antimicrobials sit outside the scope of this analysis. The value chain runs from active ingredient producers in India and China through formulators and originator brands to wholesalers, hospital pharmacies and payers that set reimbursement and stewardship rules.

Antibiotics lead while antifungals and UTI drugs gain pace

Why do antibiotics still hold the largest drug class share?

Based on drug class, the market is categorized into antibiotics, antivirals, antifungals and antiparasitics. Antibiotics led with a 46.0% share of 2025 value, because they treat the widest range of hospital and community infections. Antifungals grow fastest at 4.59% a year, since invasive fungal infections are rising among cancer, transplant and intensive care patients. Antivirals hold a large and steady base, anchored by lifelong HIV therapy and seasonal influenza treatment.

Which infections account for the most treatment spending?

Based on indication, the market is categorized into HIV infection, pneumonia, respiratory virus infection, sepsis, urinary tract infection, skin and soft-tissue infections and others. HIV Infection led with a 26.0% share of 2025 value, because patients stay on combination antiretroviral therapy for life. Urinary Tract Infection grows fastest at 4.67% a year, as new oral agents reach women with resistant or recurrent infections. Respiratory virus spending has normalized since the pandemic peak, so its growth trails the other indications.

How is long-acting dosing changing the route mix?

Based on route of administration, the market is categorized into oral, parenteral, topical, inhalation and other routes. Oral products led with a 52.0% share of 2025 value, because most community infections and HIV regimens are treated with tablets. Parenteral products grow fastest at 4.60% a year, helped by long-acting injectable antiretrovirals and intravenous reserve antibiotics. Topical and inhaled products serve narrower dermatology and respiratory niches with modest growth.

Where do patients and hospitals buy these medicines?

Based on distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, online pharmacies and others. Hospital Pharmacies led with a 44.0% share of 2025 value, because intravenous antibiotics, antifungals and sepsis treatment start on the ward. Online Pharmacies grow fastest at 6.10% a year, as mail-order HIV refills and telehealth prescribing move volume away from store counters. Retail pharmacies remain the main outlet for short oral courses written in primary care.

Resistance, HIV prevention and aging patients lift demand

How is antimicrobial resistance raising demand for newer agents?

Resistance is the strongest single driver of value, because resistant infections push prescribers from cheap generics toward newer branded agents. The World Health Organization announced in October 2025 that one in six laboratory-confirmed bacterial infections worldwide in 2023 were resistant to antibiotic treatment. More than 40% of E. coli and over 55% of K. pneumoniae isolates are now resistant to third-generation cephalosporins, the first-choice treatment. As a result, hospitals are adding reserve agents and new combinations that cost far more than first-line drugs, which raises spending per patient.

Why does lifelong HIV therapy keep antiviral demand stable?

HIV treatment and prevention form a recurring demand base, because people living with HIV take antiretrovirals every day for life. According to the UNAIDS global HIV fact sheet, 41.0 million people were living with HIV in 2025 and 32.1 million were accessing antiretroviral therapy. This gap of roughly 8.9 million people, including about 5.0 million who did not know their status, is unmet demand that programs and donors aim to close. In turn, generic fixed-dose combinations expand volume in Africa and Asia, while branded regimens hold value in high-income countries.

Download Free Sample

How does an aging population lift infection treatment volumes?

Aging populations lift treatment volumes, because older adults face higher rates of pneumonia, urinary tract infections, sepsis and shingles. This demand is concentrated in Japan, Western Europe and North America, where adults aged 65 and over make up a growing share of hospital admissions. Older patients also carry more catheters, implants and chronic conditions that raise the risk of hospital-acquired infections. As a result, hospitals buy more intravenous antibiotics and antifungals per admission, a pattern that strengthens through the 2030s.

Why are new oral agents for urinary infections expanding the market?

Urinary tract infections are a large outpatient indication, and GSK estimates that uncomplicated cases affect up to 16 million women in the U.S. each year. In April 2024, the U.S. Food and Drug Administration approved Pivya (pivmecillinam) tablets for uncomplicated urinary tract infections in adult women. Rising resistance to older oral drugs had created room for this kind of new branded option. Because these drugs keep patients at home, payers and prescribers in the United States are adopting them first, and growth follows in other regions.

Long-acting antivirals and new oral antibiotic classes rise

Is twice-yearly HIV prevention shifting the antiviral mix?

Long-acting dosing is the clearest shift in antiviral prescribing, because it removes the daily pill burden that limits adherence. In June 2025, the U.S. Food and Drug Administration approved Gilead's Yeztugo (lenacapavir) as the first twice-yearly injection for HIV pre-exposure prophylaxis in people weighing at least 35 kilograms. The World Health Organization then recommended injectable lenacapavir as an additional prevention option in July 2025. This shift moves value toward parenteral products and clinic-administered dosing, and it raises the share of spending that flows through specialty pharmacies.

Are first-in-class oral antibiotics returning to primary care?

New mechanisms of action are emerging in oral antibiotics after decades in which most launches targeted hospital use. GSK's Blujepa (gepotidacin) received U.S. approval in March 2025 as the first new oral class for uncomplicated urinary tract infections in nearly 30 years, and it was cleared again in December 2025 for uncomplicated urogenital gonorrhea. This rise of oral first-in-class agents matters, because primary care prescriptions reach far more patients than hospital formularies. As a result, branded antibiotic spending is increasing in retail and online channels as well as on wards.

Download Free Sample

Where can generic makers capture growth in HIV prevention access?

Generic manufacturers have a clear opening in high-incidence, resource-limited countries, where donors fund large volumes at low prices. In October 2024, Gilead signed royalty-free licenses with six generic makers, including Dr. Reddy's Laboratories, to supply lenacapavir in 120 primarily low- and lower-middle-income countries. This model gives Indian producers, which already supply a large share of donor-funded antiretrovirals, a route into long-acting products. In turn, volume growth in Africa and South Asia offsets lower prices for suppliers that win donor tenders.

Can antifungal pipelines open a premium hospital niche?

Antifungals offer an opening for companies with novel agents, because invasive fungal infections carry high mortality and few treatment options. Patients receiving chemotherapy, organ transplants or intensive care face the highest risk, and hospitals in North America, Europe and Japan pay premium prices for effective therapy. Astellas and Pfizer already hold established antifungal franchises, and newer agents are moving through late-stage trials. As a result, antifungals can grow faster than the overall market, provided developers secure formulary listings and stewardship approval.

Weak antibiotic returns and stewardship curb value

Why do new antibiotics struggle to earn a return?

Weak commercial returns remain the main barrier, because stewardship rules reserve new antibiotics for resistant cases and keep volumes low. In September 2024, world leaders at the UN General Assembly committed to cut the estimated 4.95 million deaths associated with bacterial resistance by 10% by 2030. The same declaration set a target that at least 70% of human antibiotic use should come from the WHO Access group, which carries a lower resistance risk. This goal protects public health, but it limits early volumes for new branded agents.

How does generic price erosion limit value growth?

Generic price erosion caps value growth across older antibiotics and antiretrovirals, because dozens of manufacturers compete in tenders for the same molecules. In India and China, active ingredient producers keep costs low, and buyers in Latin America and Africa award contracts mainly on price. This pressure means volume growth does not translate into proportional value growth. As a result, companies offset erosion by launching combination products, pediatric formulations and long-acting versions that carry better margins.

Do supply shortages put basic antibiotics at risk?

Supply concentration is a persistent risk, because a few active ingredient plants in China and India supply many essential antibiotics worldwide. Low prices leave little margin for redundant capacity, so a single plant failure can trigger shortages of amoxicillin or penicillin across several countries. Regulators in Europe and the United States have responded with shortage lists and stockpiling guidance for critical medicines. However, these measures add cost for manufacturers, and the pressure on margins is highest in pediatric formulations.

Why does access remain limited in high-burden regions?

Access gaps constrain growth where the burden is highest, because many patients in low-income countries cannot pay for newer agents. The World Health Organization estimates that one in three reported infections were resistant in its South-East Asia and Eastern Mediterranean regions in 2023. In the African Region, resistance to first-choice cephalosporins exceeds 70%, yet diagnostic networks and spending per patient remain the weakest. In turn, companies rely on tiered pricing, licensing and donor funding to reach these patients, which limits revenue per treatment course.

North America leads as Asia Pacific gains on access

Why does North America hold the largest regional share?

North America held a 36.0% share of 2025 value and grows at 3.60% a year through 2035. The United States drives this position, because branded HIV regimens, long-acting prevention and novel hospital antibiotics sell at the highest net prices in the world. Recent U.S. approvals for urinary tract infection and HIV prevention products reach this region first. However, generic substitution in older antibiotics and payer pressure on antiretroviral prices keep regional growth below the global rate.

How fast is Asia Pacific catching up?

Asia Pacific held a 27.0% share of 2025 value and is the fastest-growing region at 5.10% a year. China and India combine large infection burdens with expanding insurance coverage, which lifts the number of patients treated with branded and generic agents. India is also a leading supplier of generic antiretrovirals and antibiotics, giving companies such as Lupin, Dr. Reddy's and Glenmark scale at home and abroad. Japan adds a high-value hospital market for antifungals and reserve antibiotics.

Download Free Sample

What shapes demand across Europe?

Europe held a 25.0% share of 2025 value and grows at 3.50% a year, the slowest pace of the five regions. Strong stewardship programs and centralized tenders hold down antibiotic volumes and prices across Germany, France, the United Kingdom and the Nordic countries. However, the region leads on pull incentives, with subscription-style payments being tested to reward new antibiotics. HIV treatment remains a stable block of spending, as most diagnosed patients in Western Europe are already on therapy.

Where is Latin America adding demand?

Latin America held a 7.0% share of 2025 value and grows at 4.60% a year through 2035. Brazil and Mexico lead regional demand, supported by public HIV programs that buy antiretrovirals centrally and by rising hospital use of broad-spectrum antibiotics. Resistance in intensive care units is pushing hospitals toward newer combinations, although budget limits slow adoption.

What limits growth in the Middle East and Africa?

The Middle East and Africa held a 5.0% share of 2025 value and grows at 4.70% a year through 2035. Sub-Saharan Africa carries the largest HIV burden in the world, but donor-funded generics keep spending per patient low. Gulf states add higher-value hospital demand for reserve antibiotics and antifungals in modern tertiary care centers.

Download Free Sample

Approvals and access deals reshaping infection care

Novel mechanisms and twice-yearly dosing set the pipeline

• Capsid inhibitors such as lenacapavir allow dosing every six months, which reduces adherence gaps in both HIV treatment and prevention.
• Novel antibacterial mechanisms such as the triazaacenaphthylene class used in gepotidacin inhibit bacterial DNA replication at a distinct binding site, which helps against strains resistant to older drugs.
• Beta-lactamase inhibitor combinations pair established antibiotics with inhibitors that block resistance enzymes, which extends the useful life of proven molecules in intensive care.
• Rapid diagnostics that identify pathogens and resistance genes within hours let clinicians switch earlier from broad-spectrum to targeted therapy, which supports stewardship goals.

HIV franchises and generic antibiotic makers split the field

Competition splits between originators that hold patented HIV, antifungal and novel antibacterial franchises and generic manufacturers that supply most volume. Gilead Sciences leads HIV treatment and prevention, while GlaxoSmithKline competes through ViiV Healthcare and its new oral antibiotic portfolio. Merck & Co. and Pfizer hold hospital antibiotic and antifungal brands, and Astellas Pharma remains strong in hospital antifungals. Bristol-Myers Squibb and Abbott Laboratories maintain legacy anti-infective lines, while Bayer, Novartis and Sanofi serve primary care antibiotic and antimalarial demand. Indian producers Lupin, Dr. Reddy's Laboratories and Glenmark Pharmaceuticals compete on price in generic antibiotics and antiretrovirals, and they increasingly win donor tenders in Africa and Asia. Companies compete through new mechanisms of action, long-acting formulations, voluntary licensing and tiered pricing. The 13 companies profiled below span originators, branded generics makers and generic specialists across three continents. However, stewardship rules limit how fast any new branded agent can gain volume.

Companies profiled and their roles in this market

Value shifts to novel antibacterials and HIV prevention

Credence Research's view is that value in anti-infectives will concentrate in two places through 2035, novel agents for resistant bacterial infections and long-acting HIV medicines. Both segments command premium prices, because they solve problems that generics cannot solve, namely resistance and poor adherence. While the overall market grows at 4.12% a year, generic antibiotics will keep growing in volume, especially across Asia Pacific and Africa, but price erosion means their value share will drift lower. Companies that combine a differentiated product with a credible access plan, such as tiered pricing or voluntary licensing, are best placed to win both hospital formularies and donor tenders.

How Credence Research sized infection drug spending

The report uses 2025 as the base year and 2026 to 2035 as the forecast period. Market values come from the Credence Research model, which builds spending by drug class, indication, route of administration and distribution channel. Regional and segment splits are Credence Research estimates informed by regulator approvals, World Health Organization and UNAIDS surveillance data, and company press releases. No primary interviews or surveys were used in preparing this edition of the report.

Infection treatment spending outlook to 2035

By 2035, the anti-infectives market is projected to reach USD 235.72 billion, with growth tilted toward resistant bacterial infections, HIV prevention and invasive fungal disease. Long-acting injectables should take a larger share of antiviral spending as prevention programs scale in Africa, Asia and Latin America. New oral antibiotic classes are likely to widen branded use in primary care, although stewardship limits will keep volumes measured. Asia Pacific should add the largest number of new patients, while North America keeps the highest value per patient. As a result, advantage will depend on novel mechanisms, manufacturing scale and access partnerships.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.